```html

Bazex Syndrome (Acrokeratosis Paraneoplastica)

Overview

What it is: Bazex syndrome, also called **acrokeratosis paraneoplastica**, is a rare paraneoplastic skin disorder that appears most often in people with an underlying internal malignancy, especially squamous‑cell cancers of the upper aerodigestive tract (pharynx, larynx, esophagus). The skin changes typically involve the hands, feet, ears, and nose and often precede the cancer diagnosis by weeks to months.

Who it affects: The condition is seen predominantly in middle‑aged to older adults, with a strong male predominance (≈ 70 % of reported cases). It is most common in smokers and heavy alcohol users because these habits increase the risk of the associated cancers.

Prevalence: Exact population figures are unavailable because Bazex syndrome is rare and often under‑recognized. A review of case reports published up to 2023 identified ≈ 150 documented cases worldwide, suggesting an incidence of far less than 1 per 100,000 persons. Despite its rarity, recognizing Bazex is clinically important because the skin findings can be the first clue to a hidden malignancy.

Symptoms

The hallmark of Bazex syndrome is a symmetrical, hyperkeratotic eruption that progresses in a characteristic pattern. Symptoms may vary, but most patients experience some combination of the following:

Cutaneous manifestations

• Psoriasiform plaques: Thick, scaly, reddish‑brown plaques on the hands, forearms, feet, and lower legs. They often have a “sand‑paper” texture.
• Hyperkeratosis of the nail folds (periungual keratoderma): Thickening and scaling around the nails, sometimes causing onycholysis (separation of nail from nail bed).
• Earlobe and nasal tip involvement: Dry, cracked, or fissured skin on the helix, anti‑helix, and the tip of the nose.
• Palmar and plantar keratoderma: Diffuse thickening of the palms and soles, which can cause painful fissures.
• Hyperpigmentation or erythema: Some lesions may appear darker or more reddened than surrounding skin.

Associated systemic signs

• Unexplained weight loss, fatigue, or night sweats (often related to the occult cancer rather than the skin disease).
• Occasional pruritus (itching) at the site of lesions.
• Rarely, painful ulcerations if lesions become secondarily infected.

Because the rash frequently starts on the extremities and spreads proximally, many patients mistake it for psoriasis or eczema, delaying the correct diagnosis.

Causes and Risk Factors

Bazex syndrome is a **paraneoplastic phenomenon**—the skin changes are not caused by direct tumor invasion but by immune‑mediated or cytokine‑driven mechanisms triggered by the underlying malignancy.

Common associated cancers

• Squamous‑cell carcinoma of the head and neck (larynx, pharynx, oral cavity) – ≈ 60 % of cases.
• Esophageal squamous‑cell carcinoma – ≈ 15 %.
• Bronchial (lung) squamous‑cell carcinoma.
• Less frequently: gastric, pancreatic, or urinary‑tract cancers.

Proposed pathophysiology

• Cross‑reactive antibodies: Tumor antigens may share epitopes with skin proteins, leading to an autoimmune attack on keratinocytes.
• Cytokine release: Tumors produce tumor‑necrosis factor‑α (TNF‑α), interleukin‑1, and other inflammatory mediators that stimulate keratinocyte proliferation.
• Genetic predisposition: No specific gene is identified, but HLA‑Cw6 (linked to psoriasis) appears more often in case series, suggesting a shared immunogenetic background.

Risk factors for developing Bazex syndrome

• Age > 40 years.
• Male gender.
• Current or former heavy smoker (≥ 20 pack‑years).
• Heavy alcohol consumption (≥ 3 drinks/day).
• Presence of an undiagnosed squamous‑cell carcinoma of the upper aerodigestive tract.

Diagnosis

Diagnosing Bazex syndrome requires a combination of clinical suspicion, dermatologic assessment, and thorough cancer screening.

Clinical evaluation

• History: Onset of skin lesions, progression pattern, smoking/alcohol use, weight changes, and any prior cancer diagnosis.
• Physical exam: Symmetrical, hyperkeratotic plaques on acral sites; nail changes; involvement of ears/nose.

Skin biopsy

Histopathology is not specific but helps exclude psoriasis, eczema, or fungal infection. Typical findings include:

• Hyperkeratosis with parakeratosis.
• Irregular epidermal hyperplasia.
• Sparse perivascular lymphocytic infiltrate.

Laboratory and imaging studies

1. Basic labs: CBC, comprehensive metabolic panel, ESR/CRP – may show inflammatory markers.
2. Serologic tumor markers: SCC antigen, CEA, or CA‑19‑9, depending on suspected primary site.
3. Imaging:
   • Chest, neck, and abdomen CT or MRI to look for squamous‑cell tumors.
   • PET‑CT is often employed when the primary site is occult; it has a detection rate > 80 % in paraneoplastic skin disorders.
4. Endoscopic evaluation: Flexible nasolaryngoscopy, esophagogastroduodenoscopy (EGD), or bronchoscopy when imaging suggests lesions.

Diagnostic criteria (adapted from Mayo Clinic & European Dermatology Forum)

• Typical acral hyperkeratotic skin lesions (≥ 2 sites) AND
• Presence of an internal malignancy (confirmed by histology) OR strong suspicion warranting extensive cancer work‑up.

Treatment Options

Treatment focuses on two pillars: eradication or control of the underlying malignancy, and symptomatic management of the skin disease.

Oncologic therapy (primary)

• Surgery: Curative resection of localized head‑neck or esophageal tumors often leads to rapid skin improvement (within weeks).
• Radiation therapy: Used when surgery is not feasible; skin lesions typically regress in parallel with tumor response.
• Systemic chemotherapy / immunotherapy: Platinum‑based regimens (cisplatin + 5‑FU) or checkpoint inhibitors (nivolumab, pembrolizumab) for advanced disease. Improvement of skin lesions can be a marker of therapeutic response.

Dermatologic symptom control

1. Topical therapies:
   • High‑potency corticosteroids (clobetasol propionate 0.05 %) applied BID for 2–4 weeks.
   • Calcipotriene (vitamin D analog) 0.005 % cream for plaque softness.
   • Keratolytic agents (10 % urea, salicylic acid 3 %) to reduce hyperkeratosis.
2. Systemic agents (if skin disease persists after tumor control):
   • Acitretin 25–50 mg daily (retinoid) – helpful for keratoderma, monitor liver function.
   • Low‑dose methotrexate 7.5–15 mg weekly (off‑label) – useful for inflammatory component.
   • Biologic agents (e.g., secukinumab) have anecdotal success but lack robust data; consider only in refractory cases.
3. Phototherapy: Narrow‑band UVB 3–5 times weekly can ameliorate plaques, but should be avoided in patients with photosensitive cancers.

Adjunctive measures

• Regular moisturization with ointments containing ceramides or petroleum jelly to prevent fissuring.
• Nickel‑free gloves and cushioned footwear to reduce mechanical trauma.
• Smoking cessation programs and alcohol abstinence – improve overall cancer outcomes.

Living with Bazex Syndrome

Even after successful cancer treatment, some patients experience lingering skin changes. The following strategies can improve quality of life:

• Skin care routine: Gentle, fragrance‑free cleansers; apply thick emollients after bathing while skin is still damp.
• Regular follow‑up: Dermatology visits every 3–6 months for the first two years, then annually.
• Protective footwear: Soft‑sole shoes and padded insoles to avoid painful cracks on the soles.
• Stress management: Chronic skin disease can affect mood; consider counseling, support groups, or mindfulness apps.
• Vaccinations: Keep flu, COVID‑19, and pneumococcal vaccines up to date, especially if on immunosuppressive meds.

Prevention

Because Bazex syndrome is a manifestation of hidden cancer, primary prevention centers on reducing cancer risk:

• Quit smoking: Risks of head‑neck squamous carcinoma drop by ~50 % after 10 years of abstinence (CDC).
• Limit alcohol: ≤ 2 drinks/day for men and ≤ 1 drink/day for women lowers upper‑aerodigestive cancer risk.
• Regular cancer screening: Annual oral examinations for high‑risk individuals, low‑dose CT for long‑term smokers, and prompt evaluation of persistent dysphagia or hoarseness.
• Healthy diet & exercise: A Mediterranean‑style diet and ≥ 150 min/week of moderate activity reduce overall cancer incidence.

Complications

If the underlying malignancy is not identified or treated promptly, complications can be severe:

• Progression of the primary cancer: Advanced head‑neck or esophageal cancer has a 5‑year survival of <30 %.
• Secondary skin infections: Cracked plaques are portals for bacterial (Staphylococcus aureus, Streptococcus) or fungal infection, potentially leading to cellulitis.
• Pain and functional limitation: Severe plantar keratoderma can impede walking, affecting mobility and independence.
• Psychosocial impact: Visible skin lesions may cause anxiety, depression, or social withdrawal.

When to Seek Emergency Care

---

Sources: Mayo Clinic, “Paraneoplastic skin disorders”; CDC, “Cancer Prevention”; National Cancer Institute, “Squamous Cell Carcinoma of the Head and Neck”; WHO, “Paraneoplastic Syndromes”; Cleveland Clinic, “Acrokeratosis Paraneoplastica (Bazex)”; peer‑reviewed case series, Journal of Dermatological Science 2022; Annals of Oncology 2023.

```